⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2003British Journal of CancerOpen Access

Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000

J P Basuyau M P Blanc-Vincent Jean‐Michel Bidart A Daver Laurent Deneux N. Eche Guillaume Gory-Delabaere M.-F. Pichon Jean‐Marc Riedinger

View Full Paper

Ask AI

Bookmark

Share

Abstract

Although several clinical practice guidelines have been produced for the use of serum tumour markers in the management of breast cancer, the practice remains inconsistent ( ASCO, 1996 ; ANAES, 1997 ; Bast et al, 2001 ; Mauriac et al, 2001 ). All current knowledge was therefore reviewed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Basuyau et al. (2003) studied this question.

synapsesocial.com/papers/6a94c8a248fb14c89e6d940d https://doi.org/10.1038/sj.bjc.6601082

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.Human Clinical Trial · 1996 · 353 citations
22000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Cost-Effectiveness Analysis · 2001 · 880 citations
3Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapyBritish Journal of Cancer · Thu,
4Paediatric therapeutic development workshop on desmoplastic small round cell tumoursBritish Journal of Cancer · Wed,
5Using the Geriatric Core Dataset (G-CODE) to predict mortality in older patients with cancer: development and external validationBritish Journal of Cancer · Mon,

More from British Journal of Cancer

Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancerTue,
Switches in alternatively spliced isoforms impact protein and drug interactions in melanoma, ovarian cancer, and acute myeloid leukemiaSat,
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancerWed,
ERa-induced m6A reader HNRNPC maintains DDX6 mRNA stability to promote tumor progression in ER+BCThu,
A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancerSat,